BDNF and cancer: Secondary outcome measures included differences between AYAC and HC on self‐perceived cognitive ability assessed by FACT‐Cog v3, health‐related quality of life, cancer‐related fatigue, and biomarkers (inflammatory cytokines and brain‐derived neurotrophic factor).